The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: A comparison

BJU International

Volumn 102, Issue 9, 2008, Pages 1068-1073

  Van Den Bergh, Roderick C N ^a   Roobol, Monique J ^a   Wolters, Tineke ^a   Van Leeuwen, Pim J ^a   Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Diagnosis; Mass screening; Nomogram; Prostate biopsy; Prostate cancer

Indexed keywords

FINASTERIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; FAMILY HISTORY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY;

AGED; BIOPSY, NEEDLE; FINASTERIDE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MULTIVARIATE ANALYSIS; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 53849138025     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07940.x     Document Type: Article

References (23)

1. Schroder F, Kattan MW. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol 2008 54 : 274 90
2. Cancer Risk Calculator for Prostate Cancer (Based on the PCPT). Available at: http://www.compass.fhcrc.org/edrnnci/bin/calculator/main.asp. Accessed July 2008
3. Prostate Risk Indicator (based on ERSPC). Available at: http://www.prostate-riskindicator.com/via.html. Accessed July 2008
4. Thompson IM, Ankerst DP, Chi C et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006 98 : 529 34
5. Kranse R, Roobol MJ, Schroder FH. A graphical device to represent the outcomes of a logistic regression analysis, an illustration of its possible use in prostate cancer screening and prostate cancer treatment counselling. Prostate 2008 (in press)
6. Feigl P, Blumenstein B, Thompson I et al. Design of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials 1995 16 : 150 63
7. Schroder FH, Denis LJ, Roobol M et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003 92 (Suppl. 2 1 13
8. Schroder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R. Prostate-specific antigen-based early detection of prostate cancer - validation of screening without rectal examination. Urology 2001 57 : 83 90
9. Kranse R, Beemsterboer P, Rietbergen J, Habbema D, Hugosson J, Schroder FH. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). Prostate 1999 39 : 316 22
10. Schroder FH, Kranse R. Verification bias and the prostate-specific antigen test - is there a case for a lower threshold for biopsy? N Engl J Med 2003 349 : 393 5
11. Daneshgari F, Taylor GD, Miller GJ, Crawford ED. Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies. Urology 1995 45 : 604 9
12. Haas GP, Delongchamps NB, Jones RF et al. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst 2007 99 : 1484 9
13. Roemeling S, Schroder FH. Words of wisdom. Re: needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. Eur Urol 2008 53 : 663 4
14. Chang JJ, Shinohara K, Hovey RM, Montgomery C, Presti JC Jr. Prospective evaluation of systematic sextant transition zone biopsies in large prostates for cancer detection. Urology 1998 52 : 89 93
15. Ficarra V, Novella G, Novara G et al. The potential impact of prostate volume in the planning of optimal number of cores in the systematic transperineal prostate biopsy. Eur Urol 2005 48 : 932 7
16. Eskicorapci SY, Guliyev F, Akdogan B, Dogan HS, Ergen A, Ozen H. Individualization of the biopsy protocol according to the prostate gland volume for prostate cancer detection. J Urol 2005 173 : 1536 40
17. Basillote JB, Armenakas NA, Hochberg DA, Fracchia JA. Influence of prostate volume in the detection of prostate cancer. Urology 2003 61 : 167 71
18. Remzi M, Djavan B, Wammack R et al. Can total and transition zone volume of the prostate determine whether to perform a repeat biopsy? Urology 2003 61 : 161 6
19. Vashi AR, Wojno KJ, Gillespie B, Oesterling JE. A model for the number of cores per prostate biopsy based on patient age and prostate gland. J Urol 1998 159 : 920 4
20. Postma R, Schroder FH, van Leenders GJ et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) - Section Rotterdam. A comparison of two rounds of screening. Eur Urol 2007 52 : 89 97
21. Schroder FH, Bangma CH, Roobol MJ. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/mL? A comparison of biopsy results of PCPT and outcome-related information from ERSPC. Eur Urol 2008 53 : 901 8
22. Parekh DJ, Ankerst DP, Higgins BA et al. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population. Urology 2006 68 : 1152 5
23. Chun FK, Karakiewicz PI, Briganti A et al. Prostate cancer nomograms: an update. Eur Urol 2006 50 : 914 26